Investigational drug · Phase 3
Tirabrutinib
Also called: ONO-4059
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pemphigus, Steroid-resistant Pemphigus, Relapsed/Refractory Primary Central Nervous System Lymphoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
16
Any phase or sponsor naming "Tirabrutinib"
First trial start
2021
Dec 29, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tirabrutinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pemphigus
- Steroid-resistant Pemphigus
- Relapsed/Refractory Primary Central Nervous System Lymphoma
- Refractory Primary Central Nervous System Lymphoma
- Primary CNS Lymphoma
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Tirabrutinib" as an intervention, largest first.
Loxo Oncology, Inc.Eli Lilly (LLY)
NCT03740529 · 803 participants · Start Mar 15, 2019 · Primary completion Jan 27, 2025
Drug: Pirtobrutinib; Venetoclax and 1 more · For: Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma and 3 more
Sites: Scottsdale, Arizona; San Diego, California; San Francisco, California · 56 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT02457598 · 203 participants · Start Jun 16, 2015 · Primary completion Sep 25, 2024
Drug: Tirabrutinib; Idelalisib and 2 more · For: B-cell Malignancies
Sites: Washington D.C., District of Columbia; Goshen, Indiana; Portland, Oregon · 15 sites in all
- A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)Active, not recruiting
NCT03162536 · 190 participants (planned) · Start Jun 26, 2017 · Primary completion Sep 17, 2027
Drug: Nemtabrutinib · For: Lymphoma, B-Cell; Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia and 6 more
Sites: Scottsdale, Arizona; Los Angeles, California; Denver, Colorado · 10 sites in all
- Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's SyndromePivotal-lookingCompleted
Gilead SciencesGilead Sciences (GILD)
NCT03100942 · 152 participants · Start May 1, 2017 · Primary completion Jan 10, 2019
Drug: Lanraplenib; Filgotinib and 4 more · For: Sjogren's Syndrome
Sites: Mesa, Arizona; Phoenix, Arizona; Covina, California · 53 sites in all
- IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)Pivotal-lookingRecruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT07104032 · 132 participants (planned) · Start Jun 12, 2026 · Primary completion Dec 2027
Drug: Tirabrutinib; Rituximab and 1 more · For: Relapsed/Refractory Primary Central Nervous System Lymphoma
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fullerton, California · 50 sites in all
- Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)Active, not recruiting
Ono Pharmaceutical Co., Ltd.Industry
NCT04947319 · 119 participants · Start Dec 29, 2021 · Primary completion Jan 27, 2026
Drug: Tirabrutinib; Tirabrutinib and 1 more · For: Refractory Primary Central Nervous System Lymphoma; Primary CNS Lymphoma
Sites: Birmingham, Alabama; Phoenix, Arizona; Duarte, California · 39 sites in all
Kyorin UniversityAcademic, hospital or other
NCT06940791 · 92 participants (planned) · Start Oct 6, 2023 · Primary completion Feb 2030
Drug: Tirabrutinib; Placebo · For: Primary Central Nervous System Lymphoma
Sites: Tokyo, Japan
Gilead SciencesGilead Sciences (GILD)
NCT01659255 · 90 participants · Start Aug 17, 2012 · Primary completion Feb 23, 2015
Drug: Tirabrutinib · For: Non Hodgkins Lymphoma; Chronic Lymphocytic Leukaemia
Sites: Lille, France; Lyon, France; Montpellier, France · 6 sites in all
Gilead SciencesGilead Sciences (GILD)
NCT02626026 · 42 participants · Start Jan 26, 2016 · Primary completion Sep 1, 2016
Drug: Tirabrutinib; Placebo · For: Rheumatoid Arthritis
Sites: Sacramento, California; Miami, Florida; Orlando, Florida · 9 sites in all
Ono Pharmaceutical Co., Ltd.Industry
NCT07198087 · 40 participants · Start Oct 1, 2025 · Primary completion Apr 9, 2026
Drug: Tirabrutinib · For: Primary Central Nervous System Lymphoma (PCNSL)
Sites: Chandler, Arizona; Miami Lakes, Florida; Orlando, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Impact of nasogastric administration using the simple suspension method on serum tirabrutinib levels: A case report.
Yashima H, Araki T, Kaneta A, et al. · Am J Health Syst Pharm 2026
- Efficacy and safety of tirabrutinib monotherapy for relapsed/refractory primary CNS lymphoma: PROSPECT phase 2 trial.
Grommes C, Nayak L, Kallam A, et al. · Blood 2026
- Timing of autologous stem cell transplantation and induction response in central nervous system lymphoma.
Higuchi Y, Tatetsu H, Hirano T, et al. · Int J Hematol 2026
- Durable Complete Remission Achieved by Tirabrutinib Rechallenge in Relapsed Primary Central Nervous System Lymphoma: A Case Report.
Achiha T, Takano K, Tada Y, et al. · NMC Case Rep J 2026
- A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART).
Kawabata K, Ohka F, Saito R, et al. · Jpn J Clin Oncol 2026
- Severe Central Nervous System Fungal Infection Following Tirabrutinib Administration in a Patient with Refractory Primary Central Nervous System Lymphoma: A Case Report.
Akimoto J, Nakamura Y, Fukuhara H · NMC Case Rep J 2026
Also in development for Pemphigus
- B007Phase 33 trials
Shanghai Jiaolian Drug Research and Development Co., Ltd · Pemphigus, Primary Membranous Nephropathy, Generalized Myasthenia Gravis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.